Biologics for Asthma: Safety Data Reassures Clinicians

Reassuring data suggest that biologic therapies used to treat severe asthma do not increase the risk of respiratory infections. This finding addresses a key concern among clinicians and patients regarding the potential downsides of these powerful medications, and supports their continued use in appropriate cases.

Understanding Biologics for Asthma

Asthma is a chronic inflammatory disease of the airways. For many, traditional treatments like inhaled corticosteroids and bronchodilators are effective. However, a subset of patients experience severe asthma – a condition that doesn’t respond well to these standard therapies. Biologic therapies represent a newer class of asthma treatments, targeting specific components of the immune system that drive inflammation. Currently approved biologics for asthma include omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab. Medscape’s Foundations of Asthma provides a detailed overview of when clinicians should consider these therapies.

The concern about respiratory infections stems from the fact that biologics often suppress parts of the immune system. Whereas this suppression is targeted to reduce airway inflammation, there was a question of whether it might also leave patients more vulnerable to viruses and bacteria that cause respiratory illnesses. Recent evidence, however, indicates this isn’t necessarily the case.

Non-Clinical Factors Drive Treatment Discontinuation

A recent report in Medscape Medical News highlights that non-clinical factors are more likely to lead patients to stop biologic therapy than side effects, including concerns about infection. This suggests that while the possibility of infection is a consideration, it’s not the primary driver of treatment discontinuation. This is a crucial distinction, as it implies that the perceived risk may outweigh the actual risk for many patients.

Comorbidities and Targeted Therapies

The choice of which biologic to use is becoming increasingly nuanced. As detailed in a 2025 publication in the Journal of Clinical Medicine, “Biologic Therapies for Severe Asthma: Current Insights and Future Directions”, clinicians are now considering comorbidities – the presence of other conditions – when selecting a biologic. For example, dupilumab, mepolizumab, and omalizumab are also approved for chronic rhinosinusitis with nasal polyps (CRSwNP), a common condition among people with asthma. Using the same biologic for both conditions can simplify treatment and potentially improve outcomes.

What the Research Shows About Infection Risk

While the Medscape report doesn’t detail specific study findings on infection rates, it points to a broader trend of reassurance regarding the safety profile of biologics. It’s important to understand that assessing infection risk in asthma patients is complex. Asthma itself can increase susceptibility to respiratory infections. Studies need to carefully compare infection rates in patients on biologics to those not on biologics, while also accounting for the severity of their asthma and other risk factors.

The 2025 Journal of Clinical Medicine article notes that several clinical trials are currently underway to further investigate the efficacy and safety of biologics for severe asthma, which will likely provide more detailed data on infection rates in the future. These trials are essential for refining our understanding of the long-term effects of these therapies.

What Does This Mean for Patients?

For individuals with severe asthma who are considering or currently using biologic therapies, this information offers a degree of reassurance. It suggests that the fear of increased respiratory infections shouldn’t be a major barrier to accessing potentially life-changing treatment. However, it’s crucial to remember that no medication is entirely without risk. Patients should continue to practice good hygiene – frequent handwashing, avoiding close contact with sick individuals – and follow their healthcare provider’s recommendations for vaccinations, such as the annual influenza vaccine and pneumococcal vaccine.

It’s also important to have an open and honest conversation with your doctor about your individual risk factors and concerns. They can assist you weigh the potential benefits of biologic therapy against the potential risks, and develop a personalized treatment plan that’s right for you.

The Evolving Landscape of Asthma Treatment

The development of biologic therapies represents a significant advance in the treatment of severe asthma. These medications offer a targeted approach to managing inflammation, potentially improving lung function and quality of life for patients who haven’t responded to traditional therapies. Ongoing research is focused on identifying biomarkers – measurable indicators of disease – that can help predict which patients are most likely to benefit from specific biologics. This personalized medicine approach promises to further optimize treatment outcomes.

Looking ahead, the focus will be on refining our understanding of the long-term effects of biologics, including their impact on infection risk and the development of resistance. Continued surveillance and data collection will be essential for ensuring the safe and effective use of these medications.

What comes next: Regulatory bodies and professional medical societies will continue to review emerging data on biologic therapies for asthma. Guidance updates are likely as new evidence becomes available, and ongoing clinical trials will provide further insights into the optimal use of these medications.